Reprogramming Adenosine‐Driven Tumor Immunosuppression With a Carrier‐Free Nanoplatform for Self‐Amplifying Antitumor Immunity
Small · 2026
DOI: 10.1002/smll.75164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2026. Verfasst von Yang Ming und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Adenosine, Neoplasms, Nanoparticles, Immunosuppression Therapy. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Shandong Cancer Hospital.
Abstract (Originalsprache)
Tumor microenvironment (TME) is a metabolically dynamic niche where dysregulated purinergic signaling plays a pivotal role in shaping antitumor immunity. Although immunogenic cell death (ICD) induces the release of extracellular ATP (eATP) to initiate immune activation, the overexpression of ectonucleotidases rapidly degrades eATP into immunosuppressive adenosine, thereby attenuating therapeutic efficacy. To overcome this challenge, we here report a biomimetic nanoplatform (CADF@TA) engineered via coordination‐driven self‐assembly that reprograms the TME into a sustained bioenergetic reservoir by promoting eATP accumulation while inhibiting its degradation into adenosine. This carrier‐free nanoplatform is constructed by co‐assembling ectonucleotidase inhibitor ARL‐67156 (ARL) and oligonucleotide (CpG) with Fe 2+ and doxorubicin (DOX). Within this architecture, DOX functions as an inducer of intracellular ATP release through ICD (“pump”), whereas ARL acts as a molecular lock that concurrently inhibits CD39 and CD73 to prevent ATP degradation (“lock”). This “pump‐and‐lock” mechanism maintains an eATP‐enriched microenvironment to promote immune cell recruitment, while CpG serves as a robust adjuvant to facilitate dendritic cell maturation and subsequent CD4 + and CD8 + T cell activation. The elicited immune response further amplifies tumor apoptosis and replenishes the eATP pool, establishing a self‐amplifying immunostimulatory feedback loop. Collectively, this work presents a carrier‐free nanoplatform that overcomes the adenosine‐mediated immunosuppression through metabolic reprogramming, enabling a self‐amplifying immunostimulatory cascade for enhanced antitumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- The Institute of Nanotechnology and Intelligence(inAl), Jinan University, Guangzhou, Guangdong, China.
- Laboratory of Advanced Materials, College of Smart Materials and Future Energy (iCOME), Fudan University, Shanghai, China.
- Center For Nuclear Medicine and Molecular Imaging (CNMMI), Shandong Cancer Hospital and Institute, Jinan, China.
ORCID-Profile: Zhichu Xiang, Xiaoyuan Chen
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Shandong Cancer Hospital
- National Key Research and Development Program of China
Zitieren
APA
Ming, Y., Xiang, Z., Zhao, M., & Chen, X. (2026). Reprogramming Adenosine‐Driven Tumor Immunosuppression With a Carrier‐Free Nanoplatform for Self‐Amplifying Antitumor Immunity. Small. https://doi.org/10.1002/smll.75164
Vancouver
Ming Y, Xiang Z, Zhao M, Chen X. Reprogramming Adenosine‐Driven Tumor Immunosuppression With a Carrier‐Free Nanoplatform for Self‐Amplifying Antitumor Immunity. Small. 2026. doi:10.1002/smll.75164
BibTeX
@article{Ming2026,
author = {Ming, Yang and Xiang, Zhichu and Zhao, Mengyao and Chen, Xiaoyuan},
title = {Reprogramming Adenosine‐Driven Tumor Immunosuppression With a Carrier‐Free Nanoplatform for Self‐Amplifying Antitumor Immunity},
journal = {Small},
year = {2026},
doi = {10.1002/smll.75164}
}
EUVIMED